<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>J-MAX DHC- dihydrocodeine bitartrate and guaifenesin liquid </strong><br>JayMac Pharmaceuticals<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>J-MAX DHC</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<span class="Bold">CIII<br><br>J-MAX DHC<br>Liquid<br>Rx Only<br><br>DESCRIPTION</span><br>Each 5 mL (one teaspoonful) for oral administration contains:<br>Dihydrocodeine Bitartrate..............................7.5 mg<br><span class="Bold">(WARNING-May be habit forming)</span><br>Guaifenesin.................................................100 mg<br><br>This product contains the following inactive ingredients:<br>Glycerin, Propylene Glycol, Sorbitol, Citric Acid, Sodium Citrate, Sodium Saccharin, Grape Flavor, FD&amp;C Red #40,<br>FD&amp;C Blue #1, Menthol Crystals, Purified Water.<br><br>This product contains ingredients of the following therapeutic classes:  Antitussive and Expectorant.<br><br>Dihydrocodeine Bitartrate is an antitussive with the chemical name Morphine-6-ol,4,5-epoxy-3-methoxy-17-methyl-,(5α,6α)-2,3-dihydroxybutanedioate (1:1) (salt).  It has the following structural formula:<br><br><div class="Figure"><img alt="Dihydrocodeine Bitartrate structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61e61344-bf91-4742-be57-d74b30cfa4ad&amp;name=MM4.jpg"></div>
<br><br>Guaifenesin is an expectorant with the chemical name 1,2-Propanediol,3-(2-methoxyphenoxy)-,(±)-.  It has the following structural formula:<br><br><div class="Figure"><img alt="Guaifenesin structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61e61344-bf91-4742-be57-d74b30cfa4ad&amp;name=MM5.jpg"></div>
<br><br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>Dihydrocodeine is a semisynthetic narcotic analgesic/antitussive related to codeine, with multiple actions qualitatively similar to those of codeine:  the most prominent of these involve the central nervous system and organs with smooth muscle components.<br><br>Guaifenesin is an expectorant, which increases respiratory tract fluid secretions and helps to loosen <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">phlegm</span> and bronchial secretions.  By reducing the viscosity  of secretions, guaifenesin increases the efficiency of the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex and of ciliary action in removing accumulated secretions from the trachea and bronchi.<br>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>This product is indicated for the temporary relief of <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> and dry, non-<span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">productive cough</span> associated with <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span> and allergies.<br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>This combination product is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to dihydrocodeine, codeine, or any of the active or inactive components listed above, or in any situation where opioids are contraindicated including significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (in unmonitored settings or in the absence of resuscitation equipment), acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, and <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.  Sympathomimetic agents are contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, severe cornary artery disease, patients with narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, and during an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic attack</span>.  This product is contraindicated in women who are pregnant.<br>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<span class="Italics">General:</span>  Considerable caution should be exercised in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, and <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>.  The elderly (60 years and older) are more likely to exhibit adverse reactions.<br><br><span class="Italics">Usage in Ambulatory Patients:</span>  Dihydrocodeine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.<br><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>: </span> <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is the most dangerous acute reaction produced by opioid agonist preparations, although it is rarely severe with usual doses.  Opioids decrease the respiratory tidal volume, minute ventilation, and sensitivity to <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span>.  <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> occurs most frequently in elderly or dibilitated patients, usually after large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration.  This combination product should be used with caution in patients with significant <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span> and in patients with a substantially decreased respiratory reserve, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.<br><br><span class="Italics">Hypertensive Effect:</span>  Dihydrocodeine, like all opioid analgesics, may cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in patients whose ability to maintain blood pressure has been compromised by a depleted blood volume or who received concurrent therapy with drugs such as phenothiazine or other agents which compromise vasomotor tone.  This product may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory patients.  This combination product should be administered with caution to patients with circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> since vasodilation produced by the drug may further reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and blood pressure.<br><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>:</span>  Dihydrocodeine can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the codeine type and has the potential of being abused.  This product should be prescribed and administered with the appropriate degree of caution (See <span class="Bold">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> </span>section).<br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<span class="Italics">General: </span> This combination product should be used with caution in elderly or debilitated patients or those with any of the following conditions:  adrenocortical insufficiency (e.g., Addison's disease); <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>; decreased respiratory reserve (including <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, severe <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, or kyphoscoliosis); <span class="product-label-link" type="condition" conceptid="377830" conceptname="Alcohol withdrawal delirium">delirium tremens</span>; <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>; <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span> or hypothyroidsim; <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or urethral structure; and toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.  The benefits and risks of opioids in patients taking monoamine oxidase inhibitors and in those with a history of drug abuse should be carefully considered.  This combination product may aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, and like all opioids, may induce or aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in some clinical settings.<br><div class="Section" data-sectionCode="34073-7">
<a name="section-6.1"></a><p></p>
<h2>Drug Interactions:</h2>
<span class="Italics">General:</span>  Sympathomimetic amines may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids.<br><br><span class="Italics">Other CNS Depressants:</span>  Patients receiving other opioid analgesics, sedatives or hypnotics, muscle relaxants, general anesthetics, centrally acting anti-emetics, phenothiazines or other tranquilizers, or alcohol concomitantly with this product may exhibit additive depressant effects on the central nervous system.  When such combination therapy is contemplated, the dose of one or both agents should be reduced.  Concomitant use of dihydrocodeine with alcohol and other CNS depressants may have an additive effect.<br><br><span class="Italics">Monoamine Oxidase Inhibitors: </span> Dihydrocodeine, like all opioids, interact with monoamine oxidase inhibitors causing central nervous system excitation and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  MAO inhibitors and beta-adrenergic blockers increase the effects of sympathomimetics.<br>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.2"></a><p></p>
<h2>Information for Patients:</h2>Patients receiving this product should be given the following information:<br><ul>
<li>This product may inhibit mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.</li>
<li>Report any adverse experiences occurring during therapy.</li>
<li>Do not adjust the dose of this product without consulting the prescribing professional.</li>
<li>Do not combine this product with alcohol or other central nervous system depressants.</li>
<li>Women of childbearing potential who become, or are planning to become pregnant should be advised to consult their physician regarding the effects of opioids and other drug use during pregnancy on themselves and their unborn child.</li>
</ul>Patients should be advised that this product is a potential drug of abuse.  They should protect it from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, and it should never be given to anyone other than the individual for whom is was prescribed.<br>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.3"></a><p></p>
<span class="Bold">Pregnancy:</span>  Teratogenic Effects -  <span class="Italics">Pregnancy Category C: </span> Animal reproduction studies have not been conducted with this product.  It is also not known whether this combination product can cause fetal harm when administered to pregnant women or can effect reproduction capacity in males and females.  This combination product should be given to pregnant woman only if clearly needed, especially during the first trimester.<br><br><span class="Italics">Nonteratogenic Effects:</span><br>Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent.  The withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.  The intensity of the syndrome does not always correlate with the duration of the maternal opioid use or dose.  There is no consensus on the best method of managing withdrawal.  Chlorpromazine 0.7-1.0 mg/kg q6h, phenobarbital 2 mg/kg q6h, and paregoric 2-4 drops/kg q4h, have been used to treat withdrawal symptoms in infants.  The duration of therapy is 4 to 28 days, with dosages decreased as tolerated.<br>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-6.4"></a><p></p>
<span class="Bold">Labor and Delivery: </span> This product is not recommended for use by women during and immediately before labor and delivery because oral opioids may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn.<br>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.5"></a><p></p>
<span class="Bold">Nursing Mothers: </span> Due to the possible passage of the ingredients into breast milk, this product should not be given to nursing mothers.<br>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.6"></a><p></p>
<span class="Bold">Pediatric Use:</span>  This product is not recommended for use in children under two years of age.  Children under two years may be more susceptible to <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, comma, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Very young children may be more susceptible to the effects, especially the vasopressor effects of sympathomimetic amines.  Appropriate studies on the relationship of age to the effects of guaifenesin have not been performed in the pediatric population.  However, no pediatric specific problems have been documented to date.<br>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-6.7"></a><p></p>
<span class="Bold">Geriatric Use</span>:  This product should be given with caution to the elderly.<br><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </span> This product should be given with caution to patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.  Since dihydrocodeine is metabolized by the liver the effects of this combination product should be monitored closely in such patients.<br><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span>  This product should be used with caution and at reduced dosage in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.<br><br><span class="Italics">Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary Tract Disease</span>:</span>  Opioids may cause <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of the sphincter of Oddi and should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span>, including <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.<br>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>The most frequently observed adverse reactions with dihydrocodeine include light-headedness, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, sedation, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.  With the exception of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, tolerance develops to most of these effects.  Other reactions that have been observed with dihydrocodeine or opioids include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4009383" conceptname="Cough suppression">cough suppression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, spasm of biliary tract, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. Physical and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> are possibilities.  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (include <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>), <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span>, granulomatous interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, severe <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">narcosis</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been reported rarely during dihydrocodeine administration.  Other reactions observed with the ingredients in this product include <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">giddiness</span>, dryness of mouth, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, cardiac <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, increased <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> (especially in children).<br>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>This combination product is subject to the provisions of the Controlled Substance Act and has been placed in Schedule III.  Dihydrocodeine can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the codeine type and therefore has the potential of being abused.  Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeat administration of dihydrocodeine, and it should be prescribed and administered with the same degree of caution appropriate to the use of other opioid medications.  Symptoms of dihydrocodeine withdrawal consist of <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>.<br>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of this product is a potentially lethal poly-drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situation, and consultation with a regional Poison Control Center is recommended.  A listing of the Poison Control Centers can be found in a standard reference such as the Physician's Desk Reference.<br><br><span class="Bold">Signs and Symptoms:<br></span>Symptoms of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include pinpoint pupils, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>,<span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin and other symptoms common with narcotic overdosage.  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. A single case of acute <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> associated with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of dihydrocodeine has been reported.<br><br><span class="Bold">Recommended Treatment:</span><br>Immediate treatment of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of this product includes support of cardiovascular function and measures to reduce further drug absorption.  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> should be induced with syrup of ipecac.  If the patient is alert and has adequate laryngeal reflexes, oral activated charcoal should follow.  The first dose should be accompanied by an appropriate cathartic.  Gastric lavage may be necessary.  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> is usually hypovolemic and should be treated with fluids.  Endotrachial intubation and respiration may be necessary.  The pure opiod antagonist naloxaone or nalmexone is a specific antidote against <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> that results from opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  Opioid antagonists should not be given in the absence of clinically significant respiratory or circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> secondary to opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  They should be administered cautiously to persons who are known, or suspected to be, physically dependent on any opioid agonist including dihydrocodeine.  In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute abstinence syndrome.  The prescribing information for the specific opioid antagonist should be consulted for details of their proper use.<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<span class="Bold">Adults and children over 12 years of age: </span> 1 to 2 teaspoonfuls (5 mL to 10 mL), every 4 to 6 hours as needed.<br><span class="Bold">Children 6 to 12 years of age: </span> 1/2 to 1 teaspoonful (2.5 mL to 5 mL), every 4 to 6 hours as needed.<br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>J-MAX DHC  is supplied as a purple, alcohol free liquid with a grape flavor in 16 fl oz (473 mL) bottles, NDC 64661-070-16.<br><br><span class="Bold">KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.  IN CASE OF ACCIDENTAL <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span>, SEEK PROFESSIONAL ASSISTANCE OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.</span><br><br>Store at controlled room temperature, 15°-30°C (59°-86°F).<br><br>Tamper evident by foil seal under cap.  Do not use if foil seal is broken or missing.<br><br>Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.<br><br><span class="Bold">Rx Only</span><br><br>Manufactured by:<br>Great Southern Laboratories<br>Houston, TX  77099<br><br>Manufactured for:<br>JayMac Pharmaceuticals<br>Sunset, LA  70584<br><br>Rev. 04/08<br><br><br><br><br><br><br><br><br><br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>Product Packaging</h1>The packaging below represents the labeling currently used.<br><br>Principal display panel and side panel for 473 mL label:<br><br><span class="Bold">NDC 64661-070-16</span><br><br><span class="Bold">J-MAX DHC<br>Liquid</span><br><br><span class="Bold">Antitussive · Expectorant</span><br><br><span class="Bold">CIII</span><br><br><span class="Bold">Each teaspoonful (5 mL) for oral <br>administration contains:</span><br>Dihydrocodeine Bitartrate....................7.5 mg<br>    <span class="Bold">(WARNING:  May be habit forming)</span><br>Guaifenesin......................................100 mg<br><span class="Bold"><br>ALCOHOL FREE<br><br>Rx Only<br><br>16 fl oz (473 mL)</span><br><br><span class="Bold">USUAL DOSAGE:  Adults and children over 12 years of age</span>: 1 to 2 teaspoonfuls (5 mL to 10 mL),<br>every 4 to 6 hours as needed.  <span class="Bold">Children 6 to 12 years of age: </span> 1/2 to 1 teaspoonful (2.5 mL to 5 mL),<br>every 4 to 6 hours as needed.<br><br>For full prescribing information see attached insert.<br><br><span class="Bold">KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.<br>IN CASE OF ACCIDENTAL <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span>, SEEK PROFESSIONAL ASSISTANCE<br>OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.</span><br><br>Store at controlled room temperature, 15°-30­°C (59°-86°F).<br><br>Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.<br><br>Tamper evident by foil seal under cap.  Do not use if foil seal is broken or missing.<br><br><span class="Bold">Rx Only</span><br><br>Mfd. by:  Great Southern Laboratories, Houston, TX  77099<br>Mfd. for:  JayMac Pharmaceuticals, Sunset, LA  70584                            Rev. 04/08<br><br><div class="Figure"><img alt="J-MAX DHC Packaging" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61e61344-bf91-4742-be57-d74b30cfa4ad&amp;name=MM1.jpg"></div>
<br><br><div class="Figure"><img alt="J-MAX DHC Packaging" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61e61344-bf91-4742-be57-d74b30cfa4ad&amp;name=MM2.jpg"></div>
<br><br><div class="Figure"><img alt="J-MAX DHC Packaging" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61e61344-bf91-4742-be57-d74b30cfa4ad&amp;name=MM3.jpg"></div>
<br><br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>J-MAX 		
					DHC</strong><br><span class="contentTableReg">dihydrocodeine bitartrate, guaifenesin liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64661-070</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Dihydrocodeine Bitartrate</strong> (Dihydrocodeine) </td>
<td class="formItem">Dihydrocodeine Bitartrate</td>
<td class="formItem">7.5 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Guaifenesin</strong> (Guaifenesin) </td>
<td class="formItem">Guaifenesin</td>
<td class="formItem">100 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">GRAPE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64661-070-16</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64661-070-15</td>
<td class="formItem">15 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">06/30/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>JayMac Pharmaceuticals
							(830767260)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Great Southern Laboratories (056139553)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Great Southern Laboratories</td>
<td class="formItem"></td>
<td class="formItem">056139553</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f3354b10-fc6e-4dcb-96b4-abbc4663e425</div>
<div>Set id: 61e61344-bf91-4742-be57-d74b30cfa4ad</div>
<div>Version: 1</div>
<div>Effective Time: 20120214</div>
</div>
</div> <div class="DistributorName">JayMac Pharmaceuticals</div></p>
</body></html>
